CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Discover effective ways to increase your savings rate, helping you reach your financial goals faster.
22,326 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Ford and Tesla report contrasting Q1 2026 results, underscoring two paths for American manufacturing. Investors weigh...
As allogene (allo) 2025 earnings loom, investors weigh pipeline progress, collaboration milestones, and cash runway. ...
P3 Health is shaping the future of value-based care with its platform. This guide breaks down what to expect from hea...
Debt service is eating a growing share of tax receipts, and new projections warn of a 2032 Social Security funding cr...
Investors scanned the markets as AMC faced dilution concerns that weighed on sentiment. This piece breaks down what h...
A high-stakes legal clash between Archer Aviation and Joby could swing how investors price the whole eVTOL space. Her...
A niche investment move places acuta capital erasca (eras) at the center of Erasca's ambitious quest in targeted canc...
Two travel giants—Vail Resorts and Viking Holdings—represent different bets on leisure demand. This analysis compares...
Retirees with $600,000 weighing a move to Portugal face a tighter budget as Lisbon prices rise. The Algarve still off...
A new, sizable stake in Cal-Maine Foods hints at investor conviction despite a halved income last quarter. This piece...
Adecoagro (AGRO) investors eye the 2025 earnings path as commodity markets, currency volatility, and crop yields shap...